pixantrone has been researched along with Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (40.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cutts, SM; Evison, BJ; Mansour, OC; Nudelman, A; Phillips, DR; Rephaeli, A | 1 |
| Abastado, JP; Therasse, P | 1 |
| Huang, W; Ji, B; Meng, L; Su, Y; Tong, G; Wang, D; Yan, D; Zhu, X | 1 |
| Bernareggi, A; Bowman, A; Byrne, B; Camboni, G; Dawson, LK; Jodrell, DI; Rye, R; Smyth, JF | 1 |
| Armand, JP; Bernareggi, A; Boige, V; Buthaut, X; Camboni, G; Faivre, S; Gatineau, M; Raymond, E; Rixe, O | 1 |
2 trial(s) available for pixantrone and Neoplasms
| Article | Year |
|---|---|
A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Dose-Response Relationship, Drug; Hematologic Diseases; Humans; Infusions, Intravenous; Isoquinolines; Middle Aged; Neoplasms; Tomography, X-Ray Computed | 2000 |
A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Biological Availability; Female; Half-Life; Hematologic Tests; Humans; Infusions, Intravenous; Isoquinolines; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Neoplasms | 2001 |
3 other study(ies) available for pixantrone and Neoplasms
| Article | Year |
|---|---|
An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells.
Topics: DNA Adducts; DNA Topoisomerases, Type II; Formaldehyde; Humans; Isoquinolines; Neoplasms; Prodrugs | 2022 |
Servier's pipeline in oncology: moving from research to patients.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell- and Tissue-Based Therapy; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Drug Discovery; Drug Industry; Humans; Immunotherapy; Isoquinolines; Lymphoma, Non-Hodgkin; Medical Oncology; Neoplasms; Precision Medicine; Protein Engineering; Protein Kinase Inhibitors; Public-Private Sector Partnerships; Topoisomerase II Inhibitors; Translational Research, Biomedical | 2016 |
Preparation of pixantrone/poly(γ-glutamic acid) nanoparticles through complex self-assembly for oral chemotherapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Transport; Cell Survival; Drug Carriers; Drug Compounding; Flow Cytometry; Humans; Hydrogen-Ion Concentration; Isoquinolines; Kinetics; Mice; Microscopy, Electron, Scanning; Nanoparticles; Neoplasms; NIH 3T3 Cells; Particle Size; Polyglutamic Acid; Spectroscopy, Fourier Transform Infrared | 2012 |